CSIMarket Company Name, Ticker, Suppliers, else..
 
Anavex Life Sciences Corp   (NASDAQ: AVXL)
Other Ticker:  
 
 
Price: $8.1900 $-0.11 -1.325%
Day's High: $8.39 Week Perf: -4.55 %
Day's Low: $ 7.79 30 Day Perf: -4.66 %
Volume (M): 1,484 52 Wk High: $ 14.44
Volume (M$): $ 12,152 52 Wk Avg: $6.72
Open: $8.02 52 Wk Low: $3.25



 Market Capitalization (Millions $) 695
 Shares Outstanding (Millions) 85
 Employees 20
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -46
 Cash Flow (TTM) (Millions $) -23
 Capital Exp. (TTM) (Millions $) 0

Anavex Life Sciences Corp
Anavex Life Sciences Corp (Anavex) is a biopharmaceutical company that focuses on the development of innovative therapies for the treatment of central nervous system (CNS) diseases. They are dedicated to addressing unmet medical needs and improving the lives of patients suffering from disorders such as Alzheimer's and Parkinson's disease.

Anavex utilizes a proprietary platform called Sigma-1 Receptor (S1R) to develop small molecule drugs that have the potential to modulate multiple CNS pathways. Their lead investigational product, ANAVEX'2-73, targets neurodegenerative and neurodevelopmental diseases. This drug has shown promising results in preclinical and clinical studies, exhibiting both disease-modifying and symptomatic benefits.

The company also has other drug candidates in its pipeline, including ANAVEX'3-71, which is being developed for the treatment of Rett syndrome and other indications. ANAVEX'3-71 has shown positive results in preclinical studies, demonstrating cognitive improvements and beneficial effects on certain molecular markers.

In addition to their drug development efforts, Anavex actively collaborates with leading academic institutions and research organizations to advance their understanding of CNS diseases and identify potential therapeutic targets. They aim to leverage cutting-edge science and technology to develop novel treatments that can significantly impact patients' lives.

Overall, Anavex Life Sciences Corp is a biopharmaceutical company focused on developing innovative therapies for CNS diseases, with a strong commitment to improving patient outcomes and addressing critical unmet medical needs.


   Company Address: 630 5th Avenue New York 10111 NY
   Company Phone Number: 689-3939   Stock Exchange / Ticker: NASDAQ AVXL


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABOS   -11.1%    
AMGN   -5.51%    
BIIB   -10.13%    
NBIX   -13.52%    
RXRX   -19.85%    
VYGR   -8.58%    
• View Complete Report
   



Clinical Study

Promising Long-Term Efficacy of Blarcamesine in Early Alzheimers Disease Insights from the Phase IIb/III Open-Label ...

Published Sat, Apr 5 2025 9:45 PM UTC

Alzheimer's disease (AD), characterized by cognitive decline and neurodegeneration, poses a significant burden on individuals, families, and healthcare systems worldwide. The search for effective treatments has gained momentum, particularly focusing on early intervention strategies. In this context, recent announcements from Anavex Life Sciences have shed light on the promis...
Clinical Study

Long-Term Benefits of Oral Blarcamesine in Early Alzheimer?s Disease Patients Revealed in New Phase IIb/III Clinica...

Published Mon, Jan 13 2025 12:48 PM UTC

In a significant development for Alzheimer?s disease treatment, recent findings from the ATTENTION-AD trial demonstrate that over three years of continuous treatment with oral Blarcamesine has resulted in substantial cognitive and functional improvements among early-stage Alzheimer?s disease patients. This Phase IIb/III clinical trial adds pivotal data to the ongoing quest f...
Clinical Study

Breaking New Ground in Alzheimer?s Treatment Blarcamesine Earns EMA Acceptance for Innovative Therapy

Published Fri, Dec 27 2024 10:52 PM UTC

In a significant advancement toward the management of Alzheimer?s disease, Blarcamesine has recently garnered acceptance for filing by the European Medicines Agency (EMA). This development positions Blarcamesine as a promising candidate for the treatment landscape of Alzheimer?s, a condition that affects millions globally and presents substantial challenges in terms of both ...
Product Service News

Blarcamesine Breakthrough A Promising Hope in Alzheimer?s Therapy

Published Sun, Jul 28 2024 9:00 PM UTC

In a significant milestone for Alzheimer?s disease (AD) research, Anavex Life Sciences has garnered attention following the presentation of results from their landmark Phase IIb/III trial of Blarcamesine, also referred to as ANAVEX2-73, at the recent Alzheimer s Association International Conference. This progresive study provides a glimmer of hope for those battling this deb...
Anavex Life Sciences Corp

AVXL's Lackluster Financial Performance Raises Concerns for Investors



Anavex Life Sciences Corp, a biopharmaceutical company, recently reported its financial results for the period ending March 31, 2024. The company experienced a narrowed net loss per share compared to the previous year, while the revenue remained unchanged. In addition, various law firms have initiated legal consultations and filed class-action lawsuits against Anavex. This article aims to analyze the significance of these financial results and explore the potential implications for the company's future.
1. Reduced Loss per Share:
Anavex Life Sciences Corp reported a narrower loss per share of $-0.13 in the financial period ending March 31, 2024, compared to $-0.17 in the previous year. This indicates that the company has made progress in reducing its financial losses. However, it is important to note that the loss per share remains negative, suggesting that the company is yet to achieve profitability.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright � 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com